Stock Taper
SCREENER COMPARE ANY 2 STOCKS
APRE
APREA THERAPEUTICS, INC.
NASDAQ
$0.84
▼ DOWN 2.50% (-0.02)

KEY STATISTICS

Market Cap$10.38 M
52w High$1.69
52w Low$0.55
Dividend Yield—
Frequency—
P/E-0.78
Volume343.10K
Shares Out.12.38M

COMPANY

LEADERSHIP

Oren Gilad
CHIEF EXECUTIVE
Oren Gilad

COMPENSATION 2026

Salary$594,880
Stock Awards$14,795
Incentive Plan Pay$0
All Other Comp.$4,006
Total$657,259

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 3, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
8

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$307.50K
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2023-02-13Reverse1:20

PRICE

$0.84 ▼ DOWN 2.50% (−$0.02)
OVERLAYS
$0.84$0.85$0.87$0.899:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.84

About Aprea Therapeutics, Inc.

https://www.aprea.com ↗

Aprea Therapeutics, based in Boston, is a clinical-stage biopharma developing novel cancer therapies targeting DNA damage response pathways, with lead candidate ATRN-119 in phase 1/2a trials.

INDUSTRY

Biotechnology

A PRODUCT APREA THERAPEUTICS, INC. IS KNOWN FOR

APR-1051
APR-1051

Aprea Therapeutics' lead program is an orally bioavailable WEE1 kinase inhibitor in Phase 1 trials, targeting DNA damage response pathways for advanced solid tumors as part of their focus on precision cancer therapies.

COMPETITORS

COMPETITOR
ATRA COMPARE
AZN COMPARE
SDGR COMPARE
ZNTL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 24.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
23.95%
HOLDERS
39
TOP 12 OF 39 · RANKED BY POSITION SIZE
Aigh Capital Management LLC
1.0M sh · $774.76K
Vestal Point Capital, LP
350.0K sh · $267.01K
Murchinson Ltd.
340.1K sh · $290.14K
Sphera Funds Management Ltd.
270.0K sh · $205.98K
Nantahala Capital Management, LLC
205.8K sh · $175.51K
Vanguard Group Inc
158.2K sh · $233.4K
Dafna Capital Management LLC
137.2K sh · $202.33K
Drw Securities, LLC
120.7K sh · $102.92K
Geode Capital Management, LLC
119.1K sh · $90.89K
Sio Capital Management, LLC
112.2K sh · $165.53K
Morgan Stanley
77.0K sh · $65.71K
Scientech Research LLC
60.3K sh · $45.99K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Duey Marc
Purchase · 12.6K shares
2026-06-16
★
DIRECTOR
Pamukcu Rifat
Purchase · 12.6K shares
2026-06-16
★
DIRECTOR
Pamukcu Rifat
Purchase · 3.1K shares
2026-06-16
★
DIRECTOR
BIZZARI JEAN-PIERRE
Purchase · 12.6K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
BCDA$1.15COMPARE
KPRX$2.62COMPARE
INAB$1.03COMPARE
ACXP$1.44COMPARE
ADIL$5.60COMPARE
APVO$2.37COMPARE
CELZ$1.14COMPARE
RNAZ$2.18COMPARE